Psychedelics like MDMA, LSD, psilocybin, and ketamine are getting a lot of buzz, especially for their potential in treating depression, PTSD, and addiction. But a new study just revealed a major concern—people who end up in the ER after using hallucinogens have a 2.6x higher risk of dying compared to the general population.
The study found that those who sought emergency care after using hallucinogens were more likely to have:
• Severe mental health conditions (like suicidal thoughts)
• Chronic illnesses (such as cancer or respiratory disease)
• A history of substance use issues
In other words, these substances might not be the direct cause of death, but they’re often used by vulnerable individuals who are already at risk.
Why Does This Matter?
Hallucinogens aren’t all the same. MDMA is a stimulant, ketamine is a dissociative, and psilocybin affects serotonin levels—each has different effects and risks. The study didn’t break them down individually, so more research is needed.
But one key takeaway is clear: If someone ends up in the ER because of hallucinogen use, they likely need serious medical and mental health support.
The Bigger Picture
As psychedelics become more accepted in therapy, it’s important to understand both their potential benefits and dangers. If you or someone you know is considering hallucinogens—whether recreationally or for mental health—make sure it’s done safely and with proper guidance.
One Response
This information about hallucinogens and their hidden risks was very eye-opening. There has been so much attention on psychedelics lately for their possible therapeutic uses in treating depression and PTSD, so it’s important to also recognize the potential dangers that come with them. The finding that individuals who end up in the ER after using hallucinogens have a 2.6 times higher risk of death compared to the general population is alarming and shows how serious these situations can be.
What stood out to me most was that the study suggests it’s not always the substances themselves causing death, but rather the vulnerability of the people using them. Those struggling with severe mental health issues, chronic illnesses, or substance use disorders are often more at risk. This really highlights the need for better mental health support and awareness before people turn to such substances for relief.
I also found it important that the study pointed out how each hallucinogen—like MDMA, LSD, psilocybin, and ketamine—affects the brain differently. This makes it clear that generalizing their effects or risks can be misleading. As research continues, we need more precise studies to fully understand how to use these substances safely in a therapeutic setting.
Overall, this study reminded me that while psychedelics might hold potential benefits, responsibility, guidance, and medical supervision are essential. Mental health care should always focus on understanding the individual’s needs first, rather than relying on substances that could worsen an already fragile condition.